Strides Shasun arm gets USFDA nod for HIV drug
New Delhi: Pharmaceutical company Strides Shasun said its wholly-owned subsidiary has received approval from the US health regulator for tenofovir disoproxil fumarate tablets, used to treat HIV-1 infections in adults.
In a BSE filing, it said Strides Pharma Global Pte. has received approval from the United States Food and Drug Administration (USFDA) for tenofovir disoproxil fumarate tablets, 300 mg.
The approved product is a generic version of Gilead's Viread tablets, for which patent expired on January 25.
Strides Shasun, which already had tentative approval for the product from the USFDA, said it will launch the product immediately.
Citing IMS sales data, the company said the US market for tenofovir disoproxil fumarate tablets is approximately USD 750 million.
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd